Continue to follow the LFA for updates on stem cell therapy research and other lupus science news. With Regenerative Therapy, also known as Stem Cell Therapy for Lupus, your rebuilding process can begin.
#Stem cell treatment for lupus trial
Phase I trial results are expected to publish soon. While achieving this harmony has proven difficult with traditional therapies, recent research suggests stem cell treatment could hold the potential in helping to manage the symptoms of this autoimmune condition. Gilkeson’s prior research on cellular therapies in lupus, including a Phase I trial of MSCs in refractory lupus and a current Phase II placebo controlled multicenter trial of MSCs in refractory lupus - read more about the study here. Any successful therapy for lupus should help to control the flare of symptoms and balance the body’s immune response. Although increased knowledge of the disease pathogenesis has improved treatment options, outcomes have plateaued as current immunosuppressive therapies have failed to prevent disease relapse in more than half of treated patients. The study also seeks to determine if MSC therapy could diminish the often debilitating long-term effects of lupus, reduce the. The LFA was acknowledged in the review study for funding Dr. Background: Lupus nephritis (LN) is the most severe organ manifestations of systemic lupus erythematosus (SLE). This Phase II study of mesenchymal stem cells is an early step in determining whether stem cell treatments hold promise as a safe, effective alternative for people with lupus who do not benefit from current treatments. While results have been mixed, some early clinical trials have found that people with refractory lupus respond well to MSC therapy, with some people going into clinical remission and others seeing significant disease improvement.
The therapy also shows promise for the treatment of refractory lupus (lupus disease that’s resistant to treatment). The majority of studies completed to date in mice assessing the use of MSCs for the treatment of lupus have reported improvement in kidney disease and life expectancy both before and after the development of lupus nephritis (LN). Gilkeson, MD, Department of Medicine, Medical University of South Carolina. The review was led by the Lupus Foundation of America’s (LFA’s) research awardee, Gary S. A newly published study reviewing the current body of scientific evidence on the safety and efficacy of stem cell therapy to treat rheumatic disease highlights the potential benefits of mesenchymal stromal cells (MSCs) – a type of stem cell – for the treatment of lupus.
0 kommentar(er)
